Ways of fighting Covid-19 still arouse many doubts. In fact, a lot has changed. The evolution of studies on the infection revealed new risk groups, the importance of early diagnosis and treatment of those infected (and not only when the infection is severe, as was advocated by medicine in the first months), in addition to effective therapies against the disease.
Practice in hospitals has also shown that four out of ten deaths from Covid-19 are due to cardiac complications, information that until recently was unknown. Aware that they must take care of the organ’s health from the beginning, doctors are now able to delay the onset of the problem.
The moving averages of deaths and new cases recorded on Sunday, 18, are of 20.051,7 e 488,1, respectively. Check below the most promising treatments and those that have already been discarded.
Covid-19: Brazil reaches lowest average of deaths in the last five months
The use of corticosteroids in patients with severe Covid-19 is one of the most effective – it reduces the risk of mortality from the disease by one third. The conclusion is of a meta-analysis released only a month ago by the World Health Organization and published in the scientific journal JAMA. The researchers looked at seven randomized clinical trials that evaluated three steroidal anti-inflammatory drugs in more than 1,700 patients worldwide. The results showed the action in three drugs – dexamethasone, hydrocortisone and methylprednisolone
Tests with Remdesivir, an antiviral that has already been used to treat Ebola and MERS (Coronavirus Respiratory Syndrome in the Middle East) show that patients with moderate and severe illness show rapid improvement in the respiratory tract and reduced fever. In Brazil, the medicine is only available for studies, while in the United States, the agency that regulates medicines (FDA) approved, in May, the emergency use for the treatment of Covid-19.
Infected earlier this month, U.S. President Donald Trump received an experimental treatment for Covid-19: a cocktail of monoclonal antibodies developed by the biotechnology company Regeneron. The drug is considered one of the most promising. The results obtained show that the patients had a faster improvement compared to other treatments and a lower viral load in the throat, which, in theory, reduces the risk of disease transmission.
Chloroquine and hydroxychloroquine
Do they work or don’t they? The Ministry of Health approved the use of medicines for early treatment. Adherents applied them together with a compound of medicines, such as the anti-inflammatory azithromycin and ivermectin, a drug for worms, right at the first signs of the disease. There are studies that claim that both are not effective for the treatment, nor for the prevention of Covid-19. The controversy remains.
Pointed at the beginning of the pandemic as promising in the treatment of infection in hospitalized patients, the remedies originally designed for HIV showed no or benefits. A study of 11,000 people conducted by the University of Oxford showed that the results “convincingly rule out any significant benefit in terms of mortality from the use of lopinavir-ritonavir”.